Alvotech (ALVO)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Alvotech Stock (ALVO) Company Profile

Healthcare (1200)

Prossima data di guadagno

Ultimi documenti SEC

ALVO's Discussions on Twitter

Confronta ALVO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALVO Alvotech	11.68	3.54B	306.77M	-618.38M	-343.00M	-1.97
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Alvotech Stock (ALVO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-29	Aggiornamento	Barclays	Equal Weight → Overweight
2023-10-20	Aggiornamento	Citigroup	Sell → Neutral
2023-09-21	Iniziato	Barclays	Equal Weight
2022-09-07	Iniziato	Morgan Stanley	Equal-Weight
2022-09-06	Downgrade	Citigroup	Buy → Sell
2022-07-26	Iniziato	Citigroup	Buy

Mostra tutto

Alvotech Borsa (ALVO) Ultime notizie

Alvotech Azioni (ALVO) Dati Finanziari

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Confronta ALVO con altri titoli

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech Borsa (ALVO) Ultime notizie

Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com

Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com

Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance

Earnings call: Alvotech reported revenues of $128 million - Investing.com India

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada

Alvotech Reports Strong Revenue Growth in 2024 - TipRanks

Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada

Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria

Alvotech earnings missed, revenue fell short of estimates - Investing.com India

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia

Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com

Alvotech Showcases Strong Financial Growth and Expansion - TipRanks

Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com

EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times

Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire

Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan

ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com

EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com

EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com

EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology

Alvotech application for Simponi biosimilar accepted by EMA - MSN

Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times

European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire

Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar - JD Supra

Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline News & Insights

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times

Alvotech to Report Financial Results for the First Nine - GlobeNewswire

Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News

Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan

Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire

FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN

Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com

Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN

Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha

Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times

Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks

Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire

Alvotech Azioni (ALVO) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ALVO